CN102438975A - 取代的芳香化合物及其药物用途 - Google Patents
取代的芳香化合物及其药物用途 Download PDFInfo
- Publication number
- CN102438975A CN102438975A CN2010800232047A CN201080023204A CN102438975A CN 102438975 A CN102438975 A CN 102438975A CN 2010800232047 A CN2010800232047 A CN 2010800232047A CN 201080023204 A CN201080023204 A CN 201080023204A CN 102438975 A CN102438975 A CN 102438975A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hydrogen
- halogen
- haloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1c(*)c(*)c(*)c(*)n1 Chemical compound Cc1c(*)c(*)c(*)c(*)n1 0.000 description 4
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/39—Unsaturated compounds containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Abstract
Description
骨髓红细胞数(106) | 红细胞(109) | |
对照 | 20.3 | 7.1 |
环磷酰胺 | 8.1 | 5.7 |
化合物I | 11.5 | 7.0 |
Claims (34)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17523509P | 2009-05-04 | 2009-05-04 | |
US61/175,235 | 2009-05-04 | ||
PCT/CA2010/000677 WO2010127440A1 (en) | 2009-05-04 | 2010-05-03 | Substituted aromatic compounds and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102438975A true CN102438975A (zh) | 2012-05-02 |
CN102438975B CN102438975B (zh) | 2015-12-16 |
Family
ID=43049874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080023204.7A Active CN102438975B (zh) | 2009-05-04 | 2010-05-03 | 取代的芳香化合物及其药物用途 |
Country Status (22)
Country | Link |
---|---|
US (4) | US8927765B2 (zh) |
EP (1) | EP2427416B1 (zh) |
JP (2) | JP2012526052A (zh) |
KR (2) | KR20120024696A (zh) |
CN (1) | CN102438975B (zh) |
AU (1) | AU2010244930B2 (zh) |
BR (1) | BRPI1015124B8 (zh) |
CA (1) | CA2761018C (zh) |
DK (1) | DK2427416T3 (zh) |
EA (1) | EA022445B1 (zh) |
ES (1) | ES2575100T3 (zh) |
HK (1) | HK1169645A1 (zh) |
HU (1) | HUE029126T2 (zh) |
IL (1) | IL216006A (zh) |
MX (1) | MX2011011757A (zh) |
MY (1) | MY156780A (zh) |
NZ (1) | NZ595978A (zh) |
PL (1) | PL2427416T3 (zh) |
PT (1) | PT2427416E (zh) |
SG (1) | SG175855A1 (zh) |
TW (1) | TWI485134B (zh) |
WO (1) | WO2010127440A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105189438A (zh) * | 2013-03-15 | 2015-12-23 | 普罗米蒂克生物科学公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN105934425A (zh) * | 2013-11-15 | 2016-09-07 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和其使用方法 |
CN105997967A (zh) * | 2010-10-27 | 2016-10-12 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN108997202A (zh) * | 2018-07-10 | 2018-12-14 | 湖南华腾制药有限公司 | 一种(5-三氟甲基-吡啶-2-基)-乙酸盐的制备方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637574B2 (en) * | 2009-05-04 | 2014-01-28 | Prometic Biosciences, Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
DK2427416T3 (en) | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
US20130225683A1 (en) * | 2010-10-27 | 2013-08-29 | Prometic Biosciences Inc. | Compounds and Pharmaceutical Compositions for Uses in Diabetes |
TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
GB201416017D0 (en) * | 2014-09-10 | 2014-10-22 | New Royal Holloway & Bedford | An Anticonvulsant Compound |
CN106999456B (zh) * | 2014-10-10 | 2020-07-10 | 里米诺生物科学有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
CN107848964B (zh) | 2015-05-14 | 2021-03-19 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和使用其的方法 |
TW201946919A (zh) | 2018-05-17 | 2019-12-16 | 威斯塔研究所 | Ebna1抑制劑晶形、其製備方法及其使用方法 |
WO2020113340A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal Biosciences Limited | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
EP4051659A1 (en) * | 2019-10-31 | 2022-09-07 | Teva Pharmaceuticals International GmbH | Solid state forms of fezagepras and process for preparation thereof |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2489348A (en) * | 1947-01-15 | 1949-11-29 | Hoffmann La Roche | Production of arylacetic acids and amides |
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
GB1465219A (en) * | 1975-02-25 | 1977-02-23 | Juste Sa | Process for the preparation of a phenyl alkonoic acid and its salts |
US4021478A (en) * | 1972-07-13 | 1977-05-03 | The Upjohn Company | Preparation of carboxylic acids from glycidonitriles with ionic lewis acids |
US4485202A (en) * | 1981-09-25 | 1984-11-27 | Sumitomo Chemical Company, Limited | Isocyanuric acid ester stabilizer |
EP0159769A1 (en) * | 1984-04-05 | 1985-10-30 | Reilly Industries, Inc. | Electrochemical oxidation of pyridine bases |
US5028604A (en) * | 1988-12-08 | 1991-07-02 | Zeria Pharmaceutical Co., Ltd. | Condensed benzene derivative |
US5104798A (en) * | 1990-02-13 | 1992-04-14 | Lonza Ltd. | Microbiological oxidation of methyl groups in heterocycles |
EP0555957A1 (en) * | 1992-01-14 | 1993-08-18 | Rhone-Poulenc Agriculture Ltd. | Pyrido 2,3-d pyridazine derivatives as herbicides |
WO2001005814A1 (en) * | 1999-07-15 | 2001-01-25 | Eli Lilly And Company | Pseudomycin n-acyl side-chain analogs |
EP1273343A1 (en) * | 2000-04-04 | 2003-01-08 | Daicel Chemical Industries, Ltd. | Method of separating imide compound |
WO2003043625A1 (en) * | 2001-11-20 | 2003-05-30 | Dompe S.P.A. | 2-aryl-propionic acids and pharmaceutical compositions containing them |
US20060111445A1 (en) * | 2003-01-13 | 2006-05-25 | Nathalie Adje | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia |
WO2007041052A2 (en) * | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2008029370A1 (en) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
WO2009024905A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2618645A (en) * | 1948-11-12 | 1952-11-18 | Bowles Albert Frank | Organic mercurials |
JPS52107837A (en) * | 1976-03-05 | 1977-09-09 | Ricoh Co Ltd | Wet type electrostatic development material |
NL7709681A (nl) * | 1976-09-08 | 1978-03-10 | Sandoz Ag | Werkwijzen voor het bereiden en toepassen van fenylazijnzuurderivaten. |
US4264582A (en) * | 1978-07-31 | 1981-04-28 | The Procter & Gamble Company | Isobutylphenylacetate anti-inflammatory composition |
JPS5656899A (en) * | 1979-10-17 | 1981-05-19 | Pilot Pen Co Ltd:The | Recording material |
FR2497524B1 (zh) | 1981-01-07 | 1985-12-13 | Rhone Poulenc Spec Chim | |
EP0268907A3 (en) | 1986-11-19 | 1990-03-21 | Carl Richard Thornfeldt | Treatment of disease conditions relating to hyperactive organelles |
JPS63236519A (ja) * | 1987-03-24 | 1988-10-03 | Ube Ind Ltd | 有害廃ガスの処理方法 |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
US5366996A (en) | 1992-12-07 | 1994-11-22 | Elford Howard L | Method of treating hemoglobinopathies |
IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
US20060074063A1 (en) | 1995-12-29 | 2006-04-06 | Fernandez-Pol Jose A | Pharmacological agent and method of treatment |
US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
JPH11343283A (ja) * | 1998-05-29 | 1999-12-14 | Koei Chem Co Ltd | ピリジンカルボン酸の製造法 |
ES2376277T3 (es) | 2006-09-01 | 2012-03-12 | Piramal Life Sciences Limited | Uso del �?cido cafeico y dervados como agentes anticancerosos. |
ZA200801666B (en) * | 2007-09-29 | 2009-01-28 | Merck & Co Inc | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2009055932A1 (en) | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
CA2704286C (en) | 2007-11-02 | 2016-08-23 | Prometic Biosciences Inc. | Medium-chain length fatty acids and glycerides as nephroprotection agents |
US8946190B2 (en) | 2007-12-19 | 2015-02-03 | Prometic Biosciences Inc. | Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer |
DK2427416T3 (en) | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
US8637574B2 (en) | 2009-05-04 | 2014-01-28 | Prometic Biosciences, Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
-
2010
- 2010-05-03 DK DK10771933.8T patent/DK2427416T3/en active
- 2010-05-03 MY MYPI2011004980A patent/MY156780A/en unknown
- 2010-05-03 PL PL10771933.8T patent/PL2427416T3/pl unknown
- 2010-05-03 TW TW099114044A patent/TWI485134B/zh not_active IP Right Cessation
- 2010-05-03 MX MX2011011757A patent/MX2011011757A/es active IP Right Grant
- 2010-05-03 SG SG2011080496A patent/SG175855A1/en unknown
- 2010-05-03 CA CA2761018A patent/CA2761018C/en active Active
- 2010-05-03 ES ES10771933.8T patent/ES2575100T3/es active Active
- 2010-05-03 KR KR1020117028778A patent/KR20120024696A/ko active Application Filing
- 2010-05-03 NZ NZ595978A patent/NZ595978A/xx not_active IP Right Cessation
- 2010-05-03 WO PCT/CA2010/000677 patent/WO2010127440A1/en active Application Filing
- 2010-05-03 CN CN201080023204.7A patent/CN102438975B/zh active Active
- 2010-05-03 EA EA201171350A patent/EA022445B1/ru not_active IP Right Cessation
- 2010-05-03 AU AU2010244930A patent/AU2010244930B2/en not_active Ceased
- 2010-05-03 PT PT107719338T patent/PT2427416E/pt unknown
- 2010-05-03 EP EP10771933.8A patent/EP2427416B1/en active Active
- 2010-05-03 BR BRPI1015124A patent/BRPI1015124B8/pt not_active IP Right Cessation
- 2010-05-03 JP JP2012508861A patent/JP2012526052A/ja not_active Ceased
- 2010-05-03 KR KR1020187001772A patent/KR101923354B1/ko active IP Right Grant
- 2010-05-03 HU HUE10771933A patent/HUE029126T2/en unknown
-
2011
- 2011-10-27 IL IL216006A patent/IL216006A/en active IP Right Grant
- 2011-11-04 US US13/289,592 patent/US8927765B2/en active Active
-
2012
- 2012-10-17 HK HK12110293.9A patent/HK1169645A1/zh not_active IP Right Cessation
-
2014
- 2014-11-12 JP JP2014229970A patent/JP5815829B2/ja active Active
- 2014-12-08 US US14/563,523 patent/US9938221B2/en active Active
-
2018
- 2018-02-07 US US15/890,927 patent/US10815183B2/en active Active
-
2020
- 2020-09-23 US US17/029,197 patent/US20210002202A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2489348A (en) * | 1947-01-15 | 1949-11-29 | Hoffmann La Roche | Production of arylacetic acids and amides |
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
US4021478A (en) * | 1972-07-13 | 1977-05-03 | The Upjohn Company | Preparation of carboxylic acids from glycidonitriles with ionic lewis acids |
GB1465219A (en) * | 1975-02-25 | 1977-02-23 | Juste Sa | Process for the preparation of a phenyl alkonoic acid and its salts |
US4485202A (en) * | 1981-09-25 | 1984-11-27 | Sumitomo Chemical Company, Limited | Isocyanuric acid ester stabilizer |
EP0159769A1 (en) * | 1984-04-05 | 1985-10-30 | Reilly Industries, Inc. | Electrochemical oxidation of pyridine bases |
US5028604A (en) * | 1988-12-08 | 1991-07-02 | Zeria Pharmaceutical Co., Ltd. | Condensed benzene derivative |
US5104798A (en) * | 1990-02-13 | 1992-04-14 | Lonza Ltd. | Microbiological oxidation of methyl groups in heterocycles |
EP0555957A1 (en) * | 1992-01-14 | 1993-08-18 | Rhone-Poulenc Agriculture Ltd. | Pyrido 2,3-d pyridazine derivatives as herbicides |
WO2001005814A1 (en) * | 1999-07-15 | 2001-01-25 | Eli Lilly And Company | Pseudomycin n-acyl side-chain analogs |
EP1273343A1 (en) * | 2000-04-04 | 2003-01-08 | Daicel Chemical Industries, Ltd. | Method of separating imide compound |
WO2003043625A1 (en) * | 2001-11-20 | 2003-05-30 | Dompe S.P.A. | 2-aryl-propionic acids and pharmaceutical compositions containing them |
US20060111445A1 (en) * | 2003-01-13 | 2006-05-25 | Nathalie Adje | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia |
WO2007041052A2 (en) * | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2008029370A1 (en) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
WO2009024905A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
Non-Patent Citations (4)
Title |
---|
DIETMAR RAKOWITZ等: "Discovery of Novel Aldose Reductase Inhibitors Characterized by an Alkoxy-Substituted Phenylacetic Acid Core", 《ARCH. PHARM. CHEM. LIFE SCI.》, vol. 339, 31 December 2006 (2006-12-31), pages 559 - 563 * |
GIORGIO ORTAR 等: "New N-Arachidonoylserotonin Analogues with Potential "Dual" Mechanism of Action against Pain", 《J. MED. CHEM.》, vol. 50, 31 December 2007 (2007-12-31), pages 6554 - 6569, XP055054980, DOI: doi:10.1021/jm070678q * |
JAMES JAMISON等: "Syntheses and Antifungal Activity of Pseudomycin Side-Chain Analogues. Part 1", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 10, 31 December 2000 (2000-12-31), pages 2101 - 2105, XP004208321, DOI: doi:10.1016/S0960-894X(00)00423-6 * |
RAMESH B.等: "Effects of Steric Bulk and Conformational Rigidity on FattyAcid Omega Hydroxylation by a Cytochrome P450 4A1 Fusion Protein1", 《ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS》, vol. 334, no. 1, 31 December 1996 (1996-12-31), pages 59 - 66 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997967A (zh) * | 2010-10-27 | 2016-10-12 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN105997967B (zh) * | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN105189438A (zh) * | 2013-03-15 | 2015-12-23 | 普罗米蒂克生物科学公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN110105200A (zh) * | 2013-03-15 | 2019-08-09 | 普罗米蒂克医药Smt有限公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN110105200B (zh) * | 2013-03-15 | 2022-04-12 | 里米诺生物科学有限公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN105934425A (zh) * | 2013-11-15 | 2016-09-07 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和其使用方法 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN107106526B (zh) * | 2014-11-12 | 2021-05-28 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN108997202A (zh) * | 2018-07-10 | 2018-12-14 | 湖南华腾制药有限公司 | 一种(5-三氟甲基-吡啶-2-基)-乙酸盐的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102438975A (zh) | 取代的芳香化合物及其药物用途 | |
CN102421742B (zh) | 3-戊基苯乙酸的盐及其药物用途 | |
CN103298777B (zh) | 苯基酮羧酸盐化合物和其药学用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169645 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160725 Address after: cambridge Patentee after: The general Midike Pharmaceutical Co. Ltd. SMT Address before: Quebec Patentee before: Prometic Biosciences Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169645 Country of ref document: HK |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Substituted aromatic compounds and pharmaceutical uses thereof Effective date of registration: 20181016 Granted publication date: 20151216 Pledgee: Structured Alfa limited partnership Pledgor: The general Midike Pharmaceutical Co. Ltd. SMT Registration number: 2018990000969 |